Rezolute, Inc. 8-K

What Happened

• On March 24, 2026, Rezolute, Inc. (RZLT) issued a press release/poster reporting the results of a recent meeting with the U.S. Food and Drug Administration (FDA). The disclosure was furnished under Item 7.01 (Regulation FD Disclosure) on Form 8‑K.
• The press material is included as Exhibit 99.1 to the filing. The company states the poster contains forward‑looking statements and clarifies those statements are subject to risks and uncertainties.

Key Details

• Filing date: March 24, 2026 (Current Report on Form 8‑K, Item 7.01).
• Exhibit: 99.1 – Press Release / Poster describing the FDA meeting results.
• Regulatory note: Information is furnished under Regulation FD and is not deemed “filed” for Section 18 liability purposes nor automatically incorporated by reference in other SEC filings.
• Forward‑looking statements: The poster contains forward‑looking language and the company disclaims any obligation to update those statements except as required by law.

Why It Matters

• This 8‑K signals a regulatory update from Rezolute about interactions with the FDA, which can be material for investors tracking the company’s drug development and approval pathway.
• Investors should review the Exhibit 99.1 poster for specifics on the FDA discussion, while noting the company’s caution about forward‑looking statements and the legal limits on incorporation of this disclosure into other filings.